Controversies in the clinical evaluation of active thyroid-associated orbitopathy: Use of a detailed protocol with comparative photographs for objective assessment

Clinical Endocrinology

Volumn 55, Issue 3, 2001, Pages 283-303

  Dickinson, A Jane ^a,b   Perros, Petros ^a  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL RESEARCH; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; OPHTHALMOLOGY; ORBIT DISEASE; PHOTOGRAPHY; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TECHNIQUE; THYROID DISEASE;

CLINICAL PROTOCOLS; CONJUNCTIVAL DISEASES; EXOPHTHALMOS; EYELID DISEASES; GRAVES DISEASE; HUMANS; OCULAR MOTILITY DISORDERS; OPTIC NERVE DISEASES; PHOTOGRAPHY; SEVERITY OF ILLNESS INDEX;

EID: 0034845391     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01349.x     Document Type: Review

References (151)

1. Prevalence and clinical associations of intraocular pressure changes in Graves' disease
2. Reproducibility of clinical assessment in thyroid eye disease
3. Visual evoked potentials in hypothyroid and hyperthyroid patients before and after achievement of euthyroidism
4. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy
5. Emergency treatment of Graves' ophthalmopathy
6. Optic nerve dysfunction in thyroid eye disease: CT
7. A new ophthalmopathy index for quantitation of eye changes of Graves' disease
8. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
9. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: Comparison with systemic corticosteroids alone
10. Management of Graves' ophthalmopathy: Reality and perspectives
11. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota
12. Evolution of classification systems for Graves' ophthalmopathy
13. The treatment of Graves' ophthalmopathy in an incidence cohort
14. Clinical features of Graves' ophthalmopathy in an incidence cohort
15. Long-term follow-up of Graves ophthalmopathy in an incidence cohort
16. Early diagnosis of Graves' optic neuropathy using visual evoked responses
17. Graves' ophthalmopathy: Intracranial fat prolapse on CT images as an indicator of optic nerve compression
18. Restriction in upward gaze with advancing age
19. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease
20. Eye signs and diagnosis of thyroid orbitopathy
21. The ophthalmopathy of Graves' disease
22. Relationship of eye movement to computed tomographic findings in patients with Graves' ophthalmopathy
23. Clinical features of superior limbic keratoconjunctivitis in Australia. A probable association with thyrotoxicosis
24. Superior limbic keratoconjunctivitis: Multifactorial mechanical pathogenesis
25. The range of ocular movements decreases with aging
26. Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction
27. Racial differences in normal values of proptosis
28. Supervoltage orbital radiotherapy for Graves' ophthalmopathy
29. Appearance of Graves' disease on orbital computed tomography
30. Comparison of monocular excursion measurements in normals and in patients with motility disorders
31. Orbital decompression in Graves' ophthalmopathy associated with pretibial myxedema
32. Quantitative computed tomography of Graves' ophthalmopathy. Extraocular muscle and orbital fat in development of optic neuropathy
33. Graves' ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves' ophthalmopathy
34. Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy
35. Graves' ophthalmopathy evaluated by infrared eye-movement recordings
36. Clinical significance of extraocular muscle volumes in Graves' ophthalmopathy: A quantitative computed tomography study
37. Thyroid-associated eye disease: Clinical management
38. Extraocular muscle problems in thyroid eye disease
39. New visual acuity charts for clinical research
40. Upgaze intraocular pressure changes and strabismus in Graves' ophthalmopathy
41. Functional scoring of the field of binocular single vision
42. Ophthalmopathy of Graves' disease: Computerized volume measurements of the orbital fat and muscle
43. Is self-assessment of value in the assessment of thyroid eye disease?
44. Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease
45. Lid retraction and levator aponeurosis defects in Graves' eye disease
46. Prevalence of increased intraocular pressure in Graves' disease - Evidence of frequent subclinical ophthalmopathy
47. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy
48. Assessment of disease severity
49. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
50. The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy
51. Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters
52. Duction ranges in normal probands and patients with Graves' ophthalmopathy, determined using the Goldmann perimeter
53. Ocular surface drying and tear film osmolarity in thyroid eye disease
54. Clever is not enough: NOSPECS is form in search of function
55. The measurement of change in Graves' ophthalmopathy
56. Upper eyelid retraction and Graves' disease
57. A modified method for the reliable assessment of uniocular fields of fixation (UFOF)
58. Ocular changes in Graves' disease: A long-term follow-up study
59. Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography
60. Graves' ophthalmopathy. I. Simple CT estimates of extraocular muscle volume
61. Graves' ophthalmopathy: III. Effect of transantral orbital decompression on optic neuropathy
62. Response variability in the visual field: Comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes
63. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease
64. Pattern visual evoked potentials and pattern electroretinograms in hypothyroidism
65. Sagittal magnetic resonance imaging of dysthyroid ophthalmopathy
66. Superior limbic keratoconjunctivitis. A prognostic sign for severe Graves ophthalmology
67. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy
68. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: A controlled, randomized and prospective study
69. Prevalence and management of elevated intraocular pressure in patients with Graves' orbitopathy
70. Diabetes mellitus: A risk factor in patients with Graves' orbitopathy
71. Radiotherapy in the management of thyroid orbitopathy. Computed tomography and clinical outcomes
72. An evaluation of plasma exchange for Graves' ophthalmopathy
73. The initial clinical characteristics of Graves' orbitopathy vary with age and sex
74. Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography
75. Does decompression diminish the discomfort of severe dysthyroid orbitopathy?
76. Eyelid and orbital fascial attachments and their clinical significance
77. Orbital compartment syndrome. Direct measurement of orbital tissue pressure. 1. Technique
78. Dysthyroid ocular myopathy. Anatomy, histology, and electron microscopy
79. Reversible alteration of the visual evoked potential in hypothyroidism
80. Postural changes in IOP in dysthyroid exophthalmos
81. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy
82. Pattern visual evoked potentials in hyperthyroidism
83. Extraocular muscle surgery for Graves' ophthalmopathy: Does prior treatment influence surgical outcome?
84. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach
85. Measuring eye movements in Graves ophthalmopathy
86. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
87. Surgical management of Graves' ophthalmopathy
88. Contrast sensitivity and the diagnosis of dysthyroid optic neuropathy
89. The reliability of Hertel exophthalmometry. Observer variation between physician and lay readers
90. Intraocular pressure changes in secondary positions of gaze in normal subjects and in restrictive ocular motility disorders
91. Normal exophthalmometry
92. Dysthyroid optic neuropathy. The crowded orbital apex syndrome
93. Superior limbic keratoconjunctivitis (SLK)
94. Normal exophthalmometric values in children
95. Graves orbitopathy: Correlation of CT and clinical findings
96. Vitamin A eyedrops for superior limbic keratoconjunctivitis
97. Intraocular pressure and proptosis in 95 patients with Graves ophthalmopathy
98. Retrobulbar pressures measured during surgical decompression of the orbit
99. Quantitative CT of the orbit in Graves' disease
100. The incidence of diplopia following coronal and translid decompression in Graves' orbitopathy
101. Natural history of thyroid associated ophthalmopathy
102. Natural history of thyroid eye disease
103. Classification of eye changes of Graves' disease
104. Colour contrast sensitivity, pattern ERGs and cortical evoked potentials in dysthyroid optic neuropathy
105. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy
106. Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
107. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy
108. Medical management of Graves' ophthalmopathy
109. Assessment of disease activity of Graves' ophthalmopathy
110. The reproducibility of clinical assessment in thyroid eye disease
111. Normal variations of intraocular pressure on vertical gaze
112. Direct orbital manometry in patients with thyroid-associated orbitopathy
113. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy
114. The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement
115. Changes in saccades in endocrine orbitopathy. Clarification of the contribution by H. D. Schworm et al. 'Functional eye muscle changes in endocrine orbitopathy'
116. Clinical significance of saccade analysis in early active Graves' ophthalmopathy
117. Graves' ophthalmopathy. A clinical and immunologic review
118. E-rosette formation in Graves' ophthalmopathy
119. Graves' ophthalmopathy - Immunologic parameters related to corticosteroid therapy
120. The value of visual evoked potentials in optic neuropathy of Graves' disease
121. Enlargement of levator palpebrae superioris muscle fibers in Graves' ophthalmopathy
122. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study
123. Early detection of P-VEP and PERG changes in ophthalmic Graves' disease
124. The role of increased intraocular pressure on upgaze in the assessment of Graves ophthalmopathy
125. Quantitating the change in upper eyelid position during downgaze
126. Prevalence, natural history and surgical treatment of exophthalmos
127. A functional scoring method for the field of binocular single vision
128. Contrast sensitivity function in Graves' ophthalmopathy and dysthyroid optic neuropathy
129. Immunohistochemical staining of normal and Graves' extraocular muscle
130. Visual evoked potentials in hypothyroidism: A long-term evaluation
131. Optic nerve involvement in dysthyroidism
132. Dysthyroid optic neuropathy. Clinical profile and rationale for management
133. Correlation of CT scanning and pathologic features of ophthalmic Graves' disease
134. Flash and pattern visual evoked potentials in the diagnosis and monitoring of dysthyroid optic neuropathy
135. Orbital Graves' disease. A modification of the 'NO SPECS' classification
136. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance
137. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey
138. Classification of the eye changes of Graves' disease
139. Ultrasonic evidence of a consistent orbital involvement in Graves' disease
140. Modification of the classification of the eye changes of Graves' disease
141. Sources of error with use of Goldmann-type tonometers
142. Immunosuppressive treatment of Graves' ophthalmopathy
143. Perspectives in the management of Graves' ophthalmopathy
144. Therapeutic controversies. Retrobulbar radiation in Graves' ophthalmopathy
145. Classification of the eye changes of Graves' disease
146. Pattern EPS in endocrine orbitopathy
147. Radiotherapy for thyroid orbitopathy. Effects on extraocular muscle balance
148. Saccadic eye movements in Graves' disease
149. Superior limbic keratoconjunctivitis
150. A quantitative analysis of orbital soft tissue in Graves' disease based on B mode ultrasonography
151. Intraocular pressure changes in normal subjects and the adhesive muscle syndrome